FLT3LG and neoplasm: Consistent with the results shown above, DCP-IL-12/FLT3L plus CAR-T eradicated tumors in six out of eight mice (one mouse was killed while tumor-free), while all mice in the other groups had progressive disease (Fig. 7e–g and Extended Data Fig. 10c).